Key statistics
As of last trade WAVE Life Sciences Ltd (1U5:MUN) traded at 12.00, -32.58% below its 52-week high of 17.80, set on Dec 10, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 12.00 |
|---|---|
| High | 12.00 |
| Low | 12.00 |
| Bid | 11.40 |
| Offer | 11.60 |
| Previous close | 12.80 |
| Average volume | 166.86 |
|---|---|
| Shares outstanding | 188.25m |
| Free float | 157.63m |
| P/E (TTM) | -- |
| Market cap | 2.62bn USD |
| EPS (TTM) | -1.21 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 07:04 GMT.
More ▼
Announcements
- Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026
- Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
- Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio
- Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
- Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
- Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
- Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss
- Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025
More ▼
